ESR1 and breast carcinoma: Adjuvant treatment with tamoxifen has been established as a standard therapy for pre- and postmenopausal women with estrogen-receptor (ER)-positive early breast cancer [1–4]; however, it can stimulate pituitary-ovarian function, accompanied by increased serum estradiol (E2) levels [5].